BUZZ-India's Divi's Lab gains again on Q3 print; analysts flag good execution, key risk

Divi's Laboratories DIVI.NS rises ~5% in second session of gains post Q3 results

Co's custom synthesis segment grows 45% y/y in Q3

BOB Capital upgrades to "hold" from "sell", citing co's effective opportunity utilisation in the fast growing segment

Jefferies retains "hold" despite custom synthesis improving product mix and profit

Says co needs to overcome high rev concentration of key heart failure drug the patent for which will expire in 2026

Co working on glucose stabilising hormone GLP-1 manufacturing process to diversify

Systematix Equities says DIVI seeing interest in GLPs from several MNCs; has strong position due to backward integration

But retains "sell" on rich stock valuation

DIVI rated "hold" on avg; mean PT of 5,427 rupees is 12.2% downside to current price of 6,185.7 rupees

Stock up 66% YTD